SKYE

+ Watchlist + Portfolio

Skye Bioscience, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.60
52-Week Range: $1.50 – $18.40
Market Cap: $7.44M
P/E (TTM): —
EPS (TTM): -10.16
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -233.87%
Return on Assets: -95.06%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.95
Debt/Equity: —
Total Debt: $178.75K
Free Cash Flow: $-18.71M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-2.45M

SKYE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.01M	$5.82M	$18.70M	$42.36M
Selling, General & Admin	$6.09M	$7.85M	$17.73M	$15.80M
Operating Expenses	$12.11M	$13.67M	$36.43M	$58.16M
Operating Income	-$12.11M	-$13.67M	-$36.43M	-$58.16M
EBITDA	-$18.70M	-$36.62M	-$25.29M	-$55.20M
Pretax Income	-$19.47M	-$37.64M	-$26.56M	-$55.92M
Income Tax	$6.74K	$3.60K	$10.07K	$5.40K
Net Income	-$19.48M	-$37.64M	-$26.57M	-$55.92M
Diluted EPS	-8.77	-5.37	-0.73	-1.41
Diluted Shares	2.22M	7.01M	36.49M	39.66M

SKYE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.24M	$1.26M	$68.42M	$5.88M
Receivables	$74.12K	$158.24K	$5.07K	$10.47K
Current Assets	$8.94M	$11.65M	$70.83M	$27.09M
Total Assets	$9.11M	$11.94M	$72.76M	$28.31M
Current Liabilities	$12.12M	$13.90M	$4.34M	$8.21M
Total Debt	$1.98M	$4.62M	$455.59K	$273.65K
Total Liabilities	$12.12M	$14.07M	$4.61M	$8.29M
Retained Earnings	-$66.74M	-$104.38M	-$130.95M	-$186.87M
Shareholders' Equity	-$3.01M	-$2.13M	$68.15M	$20.02M
Working Capital	-$3.18M	-$2.25M	$66.49M	$18.89M
Net Debt	$659.30K	$3.12M	—	—

SKYE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.74M	-$13.95M	-$25.24M	-$43.06M
Capital Expenditure	-$28.06K	-$12.55K	-$1.60M	-$6.31K
Free Cash Flow	-$12.77M	-$13.96M	-$26.84M	-$43.07M
Depreciation & Amortisation	$115.00K	$124.25K	$298.64K	$723.35K
Stock-Based Compensation	$629.03K	$987.51K	$8.32M	$7.77M
Investing Cash Flow	$5.21M	$6.60M	-$245.62K	-$19.50M
Financing Cash Flow	-$208.79K	$16.44M	$83.56M	$29.57K
Net Change in Cash	-$7.74M	$9.09M	$58.08M	-$62.53M

SKYE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.20M	$14.34M	$9.36M	$11.47M	$7.94M	$3.94M
Selling, General & Admin	$4.56M	$3.91M	$3.91M	$3.43M	$4.74M	$3.87M
Operating Expenses	$11.76M	$18.24M	$13.26M	$14.90M	$12.67M	$7.81M
Operating Income	-$11.76M	-$18.24M	-$13.26M	-$14.90M	-$12.67M	-$7.81M
EBITDA	-$10.92M	-$17.43M	-$12.58M	-$14.26M	-$12.33M	-$10.62M
Pretax Income	-$11.10M	-$17.62M	-$12.75M	-$14.44M	-$12.51M	-$10.78M
Income Tax	$2.00K	$3.40K	$0.00	$0.00	$0.00	$3.40K
Net Income	-$11.10M	-$17.62M	-$12.75M	-$14.44M	-$12.51M	-$10.79M
Diluted EPS	-0.28	-0.44	-0.32	-0.36	-0.32	-0.27
Diluted Shares	39.65M	39.66M	39.67M	39.67M	39.68M	39.69M

SKYE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$46.42M	$23.84M	$18.44M	$5.88M	$8.15M	$8.07M
Receivables	$6.39K	$13.48K	$16.76K	$10.47K	$9.53K	$7.36K
Current Assets	$63.03M	$50.58M	$39.92M	$27.09M	$18.57M	$10.96M
Total Assets	$64.79M	$52.16M	$41.32M	$28.31M	$19.42M	$11.03M
Current Liabilities	$5.32M	$8.31M	$8.37M	$8.21M	$10.40M	$11.53M
Total Debt	$412.11K	$367.54K	$321.85K	$273.65K	$311.32K	$178.75K
Total Liabilities	$5.54M	$8.48M	$8.49M	$8.29M	$10.40M	$11.53M
Retained Earnings	-$142.05M	-$159.68M	-$172.43M	-$186.87M	-$199.38M	-$210.17M
Shareholders' Equity	$59.25M	$43.68M	$32.84M	$20.02M	$9.01M	-$497.31K
Working Capital	$57.71M	$42.27M	$31.56M	$18.89M	$8.16M	-$572.22K

SKYE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$9.19M	-$10.75M	-$13.36M	-$9.77M	-$8.56M	-$7.12M
Capital Expenditure	-$6.31K	—	—	—	—	—
Free Cash Flow	-$9.19M	-$10.75M	-$13.36M	-$9.77M	-$8.56M	-$7.12M
Depreciation & Amortisation	$177.38K	$187.07K	$178.90K	$180.01K	$172.89K	$157.60K
Stock-Based Compensation	$2.20M	$2.03M	$1.91M	$1.62M	$1.50M	$1.27M
Investing Cash Flow	-$12.81M	-$11.86M	$7.97M	-$2.80M	$10.90M	$7.14M
Financing Cash Flow	$0.00	$18.16K	$0.00	$11.41K	-$71.53K	-$101.01K
Net Change in Cash	-$21.99M	-$22.58M	-$5.40M	-$12.56M	$2.27M	-$80.66K

Market Snapshot

About

Skye Bioscience, Inc. is a clinical-stage pharmaceutical company developing cannabinoid-based therapies. The company focuses on treating metabolic diseases such as obesity and related metabolic disorders. Skye is advancing its lead compound through clinical trials for various indications.